Sulfonylurea Pharmacotherapy Regimen Adherence in a Medicaid Population: Influence of Age, Gender, and Race

Sclar, David A.; Robison, Linda M.; Skaer, Tracy L.; Dickson, W. Michael; Kozma, Chris M; Reeder, C. E.

doi:10.1177/014572179902500406

Cited by 39 publications

(41 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…9,10,12,30 For example, Paes et al examined the compliance as registered by MEMS 1 (Medication Event Monitoring System) devices of a group type 2 diabetes mellitus patients. 12 They excluded patients using a weekly dose organizer (a substantial part in an elderly population).…”

Section: Discussionmentioning

confidence: 99%

Refill compliance in type 2 diabetes mellitus: a predictor of switching to insulin therapy?

Spoelstra

Stolk

Heerdink

et al. 2003

Pharmacoepidemiology and Drug

View full text Add to dashboard Cite

SUMMARYObjective To assess whether switching to insulin therapy in patients with type 2 diabetes mellitus is associated with medication refill compliance of oral hypoglycemic agents. Research Design and Methods The PHARMO Record Linkage System was used as data source for this study. Patients with newly treated type 2 diabetes mellitus were defined as subjects in whom oral hypoglycemic therapy was initiated between 1991 and 1998. We performed a matched case-control study in this cohort. Cases were patients who switched to insulin therapy. Date of switching in the case was defined as the index date. Controls were subjects still on oral therapy on the index date, matched on duration of diabetes and calendar time. We measured the medication refill compliance in the year starting 18 months before the index date and calculated various compliance indices. Results In total, 411 cases and 411 matched controls were identified. Cases suffered more often from more severe comorbidity and used a higher number of oral hypoglycemic agents and concomitant non-diabetic drugs. The overall compliance rate did not differ significantly between cases and controls, the adjusted odds ratio (OR) was 1.3 (CI 95% 0.6-2.8). After performing multivariate logistic regression modeling, age at onset of diabetes, gender, comedication, combination therapy, and daily dosage frequency, were independently related to switching. Conclusions We were unable to confirm the hypothesis that noncompliance with treatment is more prevalent in patients with secondary failure. Other variables, like comorbidity and disease-related factors seem to play a more important role in switching to insulin therapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Refill compliance in type 2 diabetes mellitus: a predictor of switching to insulin therapy?

Spoelstra

Stolk

Heerdink

et al. 2003

Pharmacoepidemiology and Drug

View full text Add to dashboard Cite

show abstract

“…RESULTS -The systematic review was based on 20 reports that included quantitative information on adherence or persistence with diabetes medications (11)(12)(13)(14)(15)(16)(17)(18)(19)(20)(21)(22)(23)(24)(25)(26)(27)(28)(29)(30). The few studies that included laboratory data all showed HbA 1c levels Ͼ7%.…”

Section: Adherence Assessmentmentioning

confidence: 99%

“…Two reports with large proportions (58 and 70%) of patients remaining on treatment for 12-24 months included all OHAs in the analyses (11,12). However, a study of Medicaid recipients in South Carolina showed low treatment persistence (39% at 6 months) (23). Three reports (four cohorts) with smaller proportions (16 -49%) of patients remaining on treatment for 6 -12 months focused on specific drug treatments (13,16) and monotherapy/ polytherapy (15).…”

Section: Adherence Assessmentmentioning

confidence: 99%

A Systematic Review of Adherence With Medications for Diabetes

2004

View full text Add to dashboard Cite

OBJECTIVE -The purpose of this study was to determine the extent to which patients omit doses of medications prescribed for diabetes. -A literature search (1966 -2003) was performed to identify reports with quantitative data on adherence with oral hypoglycemic agents (OHAs) and insulin and correlations between adherence rates and glycemic control. Adequate documentation of adherence was found in 15 retrospective studies of OHA prescription refill rates, 5 prospective electronic monitoring OHA studies, and 3 retrospective insulin studies. RESEARCH DESIGN AND METHODSRESULTS -Retrospective analyses showed that adherence to OHA therapy ranged from 36 to 93% in patients remaining on treatment for 6 -24 months. Prospective electronic monitoring studies documented that patients took 67-85% of OHA doses as prescribed. Electronic monitoring identified poor compliers for interventions that improved adherence (61-79%; P Ͻ 0.05). Young patients filled prescriptions for one-third of prescribed insulin doses. Insulin adherence among patients with type 2 diabetes was 62-64%.CONCLUSIONS -This review confirms that many patients for whom diabetes medication was prescribed were poor compliers with treatment, including both OHAs and insulin. However, electronic monitoring systems were useful in improving adherence for individual patients. Similar electronic monitoring systems for insulin administration could help healthcare providers determine patients needing additional support.

show abstract

“…Conversely, because the half-lives of the latter two are equally short or even slightly shorter, it can be argued that a missed dose may have worse consequences. Published data on other typical twice-daily medications (metformin, glipizide and metoprolol) show that adequate adherence, defined as at least 80% of pills taken, is only 52-65% [51][52][53].…”

Section: Poor Adherence Without Inr Monitoringmentioning

confidence: 99%

Advantages and limitations of the new anticoagulants

Schulman

2013

J Intern Med

View full text Add to dashboard Cite

During recent years, three new anticoagulants (dabigatran, rivaroxaban and apixaban) have been introduced to the market, probably with one more anticoagulant (edoxaban) in the next 2 years. This review is not intended to compare the efficacy and risks of these new agents, but rather to detail the advantages and limitations. The pharmacokinetic characteristics of these drugs have few drug and food interactions, predictable dose responses, and rapid onset and offset, thus resulting in simplified management of the patient requiring anticoagulant therapy. No routine laboratory monitoring is required. A somewhat unexpected, but exciting observation involving the new anticoagulants, is the uniform reduction in intracranial bleeding by one-half compared with warfarin. The potential limitations of the new anticoagulants include uncertainty regarding assessment of drug levels, safe drug levels for major surgery, management of major bleeding, renal dependence, multiple dose regimens, adherence in the absence of frequent monitoring and unknown, rare side effects that were not captured in the trials. This review should clarify some of these concerns.

show abstract

Sulfonylurea Pharmacotherapy Regimen Adherence in a Medicaid Population: Influence of Age, Gender, and Race

Cited by 39 publications

References 20 publications

Refill compliance in type 2 diabetes mellitus: a predictor of switching to insulin therapy?

Refill compliance in type 2 diabetes mellitus: a predictor of switching to insulin therapy?

A Systematic Review of Adherence With Medications for Diabetes

Advantages and limitations of the new anticoagulants

Contact Info

Product

Resources

About